A 47-year-old woman with a 2-month history of bilateral progressive visual loss was found to have a bilateral retrobulbar optic neuropathy. Her serum vitamin B12 concentration and hemoglobin level were normal, but her serum folic acid concentration was decreased. The patient had a minimal alcohol intake and moderate tobacco use that had been unchanged for over 20 years; however, she had markedly altered her diet 4 years earlier in the setting of clinical depression. After treatment with oral folic acid and diet modification without change in her tobacco or alcohol use, the patient’s visual function returned to normal. This case supports the role of folic acid deficiency as an important cause of some cases of nutritional optic neuropathy.

Keywords:
Optic neuropathy, Folic acid, Nutritional deficiency, Diet
1.
Lessell S: Toxic and deficiency optic neuropathies; in Miller NR, Newman NJ (eds): Walsh and Hoyt’s Clinical Neuro-Ophthalmology, ed 5. Baltimore, Williams & Wilkins, 1998, vol 1, pp 663–670.
2.
Chisholm IA: Serum cobalamin and folate in the optic neuropathy associated with tobacco smoking. Can J Ophthalmol 1978;13:105–109.
3.
Knox DL, Chen MF, Guilarte TR, Dang CV, Burnette J: Nutritional amblyopia. Retina 1982;2:288–293.
4.
Golnik KC, Schaible ER: Folate-responsive optic neuropathy. J Neuroophthalmol 1994;14:163–169.
5.
Heimburger DC: Nutrition’s interface with health and disease; in Bennett JC, Plum F (eds): Cecil Textbook of Medicine, ed 20. Philadelphia, Saunders, 1996, vol 2, p 1140.
6.
Nicholls P: Formate as an inhibitor of cytochrome c oxidase. Biochem Biophys Res Commun 1975;67:610–616.
7.
Martin-Amat G, McMartin KE, Hayreh SS, Hayreh MS, Tephly TR: Methanol poisoning: Ocular toxicity produced by formate. Toxicol Appl Pharmacol 1978;45:201–208.
8.
Eells JT, Makar AB, Noker PE, Tephly TR: Methanol poisoning and formate oxidation in nitrous oxide-treated rats. J Pharmacol Exp Ther 1981;217:57–61.
9.
Eells JT: Methanol-induced visual toxicity in the rat. J Pharmacol Exp Ther 1991;257:56–63.
10.
Sadun A: Acquired mitochondrial impairment as a cause of optic nerve disease. Trans Am Ophthalmol Soc 1998;96:881–923.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.